TopoTarget's Savene Recommended as Standard Treatment for Anthracycline Extravasation

TopoTarget today announced that Savene has been recommended as standard treatment for anthracycline extravasation in the new European Oncology Nursing society (EONS) guidelines.

The guidelines state that due to the high level of evidence that exists for Savene this specific antidote is changing the way antidotes are recommended:

- In the past few years, new data from preclinical and clinical studies has changed the way antidotes are used in anthracycline extravasation, particularly that for Savene. And, it has since become the only licensed specific antidote to anthracycline extravasation, states Peter Buhl Jensen, CEO of TopoTarget.

Savene was launched on the European market in 2006 and the product was launched in the US in October 2007 under the name Totect. In both markets it is the only approved therapy for anthracycline extravasations.

- I am very pleased Savene is included in EONS guidelines. We believe this strong recommendation should result in hospitals that administer anthracyclines deciding to stock Savene ready for use in case an anthracycline extravasation occurs, says Buhl Jensen. 

Read the full press release at topotarget.com.

Read the guidelines at cancerworld.org.

Source: Press release, TopoTarget, 14.01.2008.